Current opportunities:

The following compounds are currently open for out licensing and/or co-development with a strategic partner:

AIC284

Innovative treatment against autoimmunity

AIC649

Proprietary immune modulator and potential cure for chronic hepatitis B infection

If you have further questions regarding partnering of our projects please contact:

Arne Wilkens

Business Development & Alliance

AiCuris Anti-infective Cures GmbH
Friedrich-Ebert-Str. 475
42117 Wuppertal

Phone: +49 (0)202 317 63 - 0
Fax: +49 (0)202 317 63 - 1177
E-Mail: business(at)aicuris.com